Common Contracts
14 similar Executive Employment Agreement contracts by Neumora Therapeutics, Inc.
NEUMORA THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 7th, 2024 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Carol Y. Suh (“Executive” and, together with the Company, the “Parties”) effective as of January 1, 2023 (the “Effective Date”). This Agreement supersedes in its entirety that certain Executive Employment Agreement between Executive and the Company dated as of April 11, 2022 (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 7th, 2024 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason Duncan (“Executive” and, together with the Company, the “Parties”) effective as of November 13, 2023 (the “Effective Date”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Joshua Pinto (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 7, 2021 (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [________] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [_______] (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Paul Berns (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Illinois
This Executive Employment Agreement (the “Agreement”) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Henry Gosebruch (“Executive” and, together with the Company, the “Parties”) this June 2, 2023 (the “Effective Date”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and John Dunlop (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [ ] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [ ] (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Illinois
This Executive Employment Agreement (the “Agreement”) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Henry Gosebruch (“Executive” and, together with the Company, the “Parties”) this June 2, 2023 (the “Effective Date”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 30th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Joshua Pinto (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 7, 2021 (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 30th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and John Dunlop (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 30th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Paul Berns (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 2nd, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [ ] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [ ] (the “Prior Agreement”).
NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 2nd, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [________] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [_______] (the “Prior Agreement”).
